KRAS and lung adenocarcinoma: Zeng DX et al. [70] reported that four advanced lung adenocarcinoma patients with a KRAS mutation were orally administered apatinib (250 mg/d) after second-line treatment, and one patient developed manageable hoarseness and hemoptysis (grade 1).